Cargando…

Disseminated cutaneous leishmaniasis in a kidney transplant recipient

KEY CLINICAL MESSAGE: In this case of disseminated cutaneous leishmaniasis in our immunosuppressive patient who was a refractor to treatment with intra‐lesion Glucantime® and systemic L‐AmB, considering the good clinical response to oral miltefosine, this drug might be the best treatment option. ABS...

Descripción completa

Detalles Bibliográficos
Autores principales: Amiri, Rezvan, Farrokhnia, Mehrdad, Mousavi Mehdiabadi, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264955/
https://www.ncbi.nlm.nih.gov/pubmed/37323282
http://dx.doi.org/10.1002/ccr3.7549
Descripción
Sumario:KEY CLINICAL MESSAGE: In this case of disseminated cutaneous leishmaniasis in our immunosuppressive patient who was a refractor to treatment with intra‐lesion Glucantime® and systemic L‐AmB, considering the good clinical response to oral miltefosine, this drug might be the best treatment option. ABSTRACT: Diagnosis and treatment of leishmaniasis are challenging in immunosuppressed patients. Here, we report a 46‐year‐old male renal transplant recipient with disseminated cutaneous leishmaniasis presenting with multiple lesions on the face and upper extremities 15 years after transplant with a challenging course of treatment with meglumine antimoniate, liposomal amphotericin B, and miltefosine.